Capital City Trust Co. FL Acquires 417 Shares of Johnson & Johnson $JNJ

Capital City Trust Co. FL raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,011 shares of the company’s stock after acquiring an additional 417 shares during the quarter. Johnson & Johnson makes up about 1.6% of Capital City Trust Co. FL’s portfolio, making the stock its 18th biggest position. Capital City Trust Co. FL’s holdings in Johnson & Johnson were worth $6,264,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the stock. Highline Wealth Partners LLC lifted its position in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth $48,000. von Borstel & Associates Inc. purchased a new position in Johnson & Johnson during the 1st quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the 1st quarter valued at about $52,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 0.2%

NYSE JNJ opened at $188.23 on Tuesday. The company has a fifty day moving average of $176.62 and a 200 day moving average of $163.00. The company has a market capitalization of $453.32 billion, a PE ratio of 20.13, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $189.92.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the business posted $2.82 EPS. The company’s revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on JNJ shares. Royal Bank Of Canada boosted their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their target price for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $189.12.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.